STERISHEALTHCARE Products
Mumbai info@sterispharma.com
918824175417
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products MAGRAL 160
COD not available
Gynaecology by megestrol acetate 160 mg

MAGRAL 160

INR 567 INR 810
You Save: INR 243 (30%)
Check On
Share with
Check On
Share this on :

Description

Product details

MAGRAL 160 is a pharmaceutical medication containing megestrol acetate 160 mg, a synthetic progestin known for its potent antineoplastic and appetite-stimulating properties. This drug is primarily prescribed to manage significant health challenges such as unexplained weight loss, anorexia, and cachexia, especially in patients suffering from chronic conditions like cancer or AIDS. Additionally, megestrol acetate functions as a hormone therapy agent employed in the treatment of certain hormone-sensitive malignancies. Its dual action both supports tumor management and improves patients' nutritional status by stimulating appetite and promoting weight gain, thereby enhancing overall quality of life. The drug is regarded as a crucial option in oncology and palliative care for managing complex conditions related to hormone-dependent cancers and severe wasting syndromes. What is MAGRAL 160? MAGRAL 160 is an oral medication formulated with megestrol acetate 160 mg, a synthetic progestin hormone derivative. It works primarily by modulating hormone receptors and altering hormone levels that influence the growth of hormone-responsive tumors such as breast and endometrial cancers. Apart from its antineoplastic action, it stimulates appetite by acting on the hypothalamic centers responsible for hunger, helping patients suffering from severe weight loss regain a healthy appetite and weight. Uses of MAGRAL 160 To treat hormone-dependent cancers, specifically advanced breast cancer and endometrial cancer. To stimulate appetite and promote weight gain in patients experiencing anorexia, cachexia, or unexplained severe weight loss related to chronic illnesses like cancer or AIDS. To manage wasting syndromes that lead to malnutrition and significant weight loss. To serve as an antineoplastic agent in hormone-sensitive malignancies. In short, MAGRAL 160 is primarily used to treat anorexia and cachexia or serious unexplained weight loss and is also used as an antineoplastic agent to treat certain types of malignancy. Side Effects of MAGRAL 160 Weight gain (often desirable but can be excessive) Fluid retention and edema (swelling) Nausea and vomiting Diarrhea or constipation Vaginal bleeding or spotting in women Fatigue, weakness, and insomnia Headache and dizziness Increased risk of blood clots (deep vein thrombosis or pulmonary embolism) Hormonal imbalances, such as decreased sex hormone levels, which can lead to sexual dysfunction or bone density loss Allergic reactions including rash or itching Patients should report severe or unusual symptoms, especially signs of blood clots such as limb swelling, chest pain, or sudden shortness of breath, immediately to their healthcare provider. Precautions before Using MAGRAL 160 Inform your doctor if you are pregnant, breastfeeding, or planning to conceive as MAGRAL 160 is contraindicated in pregnancy. Disclose any history of blood clots, cardiovascular diseases, liver or kidney impairment. Patients with diabetes should monitor blood sugar closely as megestrol acetate may cause hyperglycemia. Avoid sudden discontinuation without medical advice to prevent potential hormonal withdrawal effects. Regular monitoring is required, including hormone levels and blood tests, to assess efficacy and safety during treatment. Use cautiously in patients at risk for deep vein thrombosis or pulmonary embolism due to increased clotting risks. Drug Interactions: What Drugs Interact with MAGRAL 160? CYP3A4 enzyme inducers (e.g., rifampin, phenytoin) may reduce the effectiveness of megestrol acetate by increasing its metabolism. Concurrent use with blood thinners (anticoagulants) requires careful monitoring as MAGRAL 160 might influence clotting parameters. Combining with drugs that affect hormonal pathways, such as other hormonal therapies or corticosteroids, may alter treatment outcomes. Interactions with diabetes medications might necessitate dose adjustment due to potential effects on blood sugar control. Careful medical supervision is necessary when used with immunosuppressants or other chemotherapy agents to avoid additive side effects or altered drug levels. Conclusion MAGRAL 160, containing megestrol acetate 160 mg, is a clinically validated medication widely used to manage complex conditions such as hormone-dependent cancers as well as severe weight loss due to anorexia and cachexia. Its unique ability to act both as an antineoplastic agent and an appetite stimulant makes it invaluable in improving patient outcomes, nutritional status, and overall quality of life. Patients prescribed MAGRAL 160 should adhere strictly to their healthcare provider’s instructions and report any adverse effects promptly. This medication should always be used under medical supervision to ensure optimal benefits and minimize risks.

  • Filter tags

Other Products

Related Products

GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control. It is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes. Mechanism of Action The therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism: 1. Glimepiride (1 mg) – Sulfonylurea Stimulates insulin secretion by activating pancreatic beta cells. Provides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas. Helps reduce both fasting and postprandial glucose levels. 2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor Delays the breakdown and absorption of carbohydrates in the intestine. Minimizes post-meal glucose spikes (PPBG). Acts locally in the gut and has minimal systemic absorption, which reduces systemic side effects. 3. Metformin Hydrochloride SR (500 mg) – Biguanide Decreases hepatic glucose production (gluconeogenesis). Improves peripheral insulin sensitivity, enhancing glucose uptake in muscles. Does not cause hypoglycemia on its own. The sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects. Indications GLIMITERIS MV1 0.2 is indicated for: Adults with Type 2 Diabetes Mellitus. Patients inadequately controlled with monotherapy or dual therapy. Management of fasting and postprandial hyperglycemia. Long-term HbA1c reduction as part of a comprehensive diabetes care plan. Key Benefits ✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels. ✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges. ✅ Reduced Pill Burden – Combines three medicines into a single tablet. ✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect. ✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain. ✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort. Dosage and Administration Recommended dose: One tablet once or twice daily with meals, or as directed by the physician. Administration tips: Take with the first bite of a main meal to maximize Voglibose’s effect. Swallow whole with water; do not crush or chew the SR tablet. Dose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function. Contraindications GLIMITERIS MV1 0.2 is not suitable for patients with: Type 1 diabetes or diabetic ketoacidosis. Severe renal impairment (eGFR <30 mL/min/1.73 m²). Hepatic dysfunction. Severe gastrointestinal diseases. History of lactic acidosis. Hypersensitivity to Glimepiride, Voglibose, or Metformin. Pregnancy and lactation (unless strictly advised by a physician). Warnings and Precautions Hypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals. Lactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential. GI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary). Vitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption. Liver and Kidney Function: Regular monitoring is recommended for safe long-term use. Adverse Effects Common: Glimepiride: Mild hypoglycemia, dizziness, slight weight gain. Voglibose: Gas, abdominal discomfort, mild diarrhea. Metformin SR: Nausea, bloating, metallic taste, loose stools. Rare but Serious: Lactic acidosis (from Metformin). Severe hypoglycemia (especially if meals are skipped). Allergic reactions such as rash, itching, or swelling. Elevated liver enzymes. Seek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur. Drug Interactions Increased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas. Reduced Metformin efficacy: With corticosteroids, estrogens, and diuretics. Lactic acidosis risk: Higher with alcohol or iodinated contrast agents.
View Details
Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg

INR263

BUDESHINE F 400 CAP - This is a combination inhalation therapy used in the management of asthma and Chronic Obstructive Pulmonary Disease (COPD). Mechanism of Action: Formoterol Fumarate: A long-acting β2-adrenergic agonist (LABA) that relaxes airway smooth muscles, providing rapid and sustained bronchodilation. Budesonide: An inhaled corticosteroid (ICS) that reduces airway inflammation, swelling, and mucus production. Together, they offer dual action—quick relief of bronchospasm and long-term control of airway inflammation. Indications: Asthma (for patients not controlled adequately with inhaled corticosteroids alone). Chronic Obstructive Pulmonary Disease (COPD) with reversible airway obstruction. Prevention of asthma attacks and reduction of COPD exacerbations. Key Benefits: Provides fast and sustained relief from breathing difficulty. Controls both inflammation and bronchospasm. Reduces the frequency and severity of asthma/COPD flare-ups. Improves overall lung function and quality of life. Dosage and Administration: Administered via inhalation as directed by a physician. Dose depends on the severity of disease and patient response. Regular use is required for effective control—not for acute asthma attacks. (Exact dosing schedule to be prescribed by the doctor.)
View Details
Formoterol Fumarate Dihydrate Ip 6 mcg & Budesonide IP 400 mcg

INR238

KEYPROFEN DT is a fast-acting nonsteroidal anti-inflammatory drug (NSAID) used to relieve moderate pain and inflammation. Its dispersible tablet form ensures quick dissolution and faster pain relief, making it convenient for oral administration. Ideal for managing post-operative pain, musculoskeletal discomfort, and other short-term pain conditions.
View Details
ketorolac tromethamine dispersible tablets 10 mg

INR166

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us